Table 1 The characteristics of all patients with lung adenocarcinoma
Variables | IFT20 protein expression | P value | GM130 protein expression | P value | ||
|---|---|---|---|---|---|---|
Negative (n = 67) | Positive (n = 168) | Negative (n = 84) | Positive (n = 151) | |||
Age (years, Mean ± SD) | 57.25 ± 9.58 | 56.20 ± 9.86 | 0.458 | 57.36 ± 9.62 | 56.03 ± 9.86 | 0.318 |
Gender, (Male, n, %) | 47(70.15) | 90(53.57) | 0.024 | 55(65.48) | 82(54.30) | 0.096 |
Smoking status (n, %) | Â | Â | 0.009 | Â | Â | 0.177 |
 Current smoking | 28(41.79) | 44(26.19) |  | 27(32.14) | 45(29.80) |  |
 Never smoking | 28(41.79) | 107(63.69) |  | 43(51.19) | 92(60.93) |  |
 Former smoking | 11(16.42) | 17(10.12) |  | 14(16.67) | 14(9.27) |  |
Smoking amount, pack-year | 22.05 ± 25.24 | 13.30 ± 23.06 | 0.011 | 20.67 ± 27.98 | 13.09 ± 21.04 | 0.020 |
Differentiated types of tumors (n, %) | Â | Â | 0.377 | Â | Â | 0.049 |
 Poorly | 20(29.85) | 51(30.36) |  | 33(39.29) | 38(25.17) |  |
 Moderately | 39(58.21) | 85(50.60) |  | 36(42.86) | 88(58.28) |  |
 Well | 8(11.94) | 32(19.05) |  | 15(17.86) | 25(16.56) |  |
Ki67 | Â | Â | 0.441 | Â | Â | 0.222 |
 < 50% | 56(83.58) | 133(79.17) |  | 64(76.19) | 125(82.78) |  |
 ≥50% | 11(16.42) | 35(20.83) |  | 20(23.81) | 26(17.22) |  |
Tumor size (cm) | 4.93 ± 2.56 | 4.43 ± 2.06 | 0.117 | 5.02 ± 2.67 | 4.32 ± 1.89 | 0.019 |
T stages (n, %) | Â | Â | 0.012 | Â | Â | 0.206 |
 T1 ~ T2 | 36(53.73) | 119(70.83) |  | 51(60.71) | 104(68.87) |  |
 T3 ~ T4 | 31(46.27) | 49(29.17) |  | 33(39.29) | 47(31.13) |  |
N stages (n, %) | Â | Â | 0.048 | Â | Â | 0.084 |
 N0 ~ N1 | 19(28.36) | 71(42.26) |  | 26(30.95) | 64(42.38) |  |
 N2 ~ N3 | 48(71.64) | 97(57.74) |  | 58(69.05) | 87(57.62) |  |
M stages (n, %) | Â | Â | 0.193 | Â | Â | 0.785 |
 M0 | 50(74.63) | 138(82.14) |  | 68(80.95) | 120(79.47) |  |
 M1 | 17(25.37) | 30(17.86) |  | 16(19.05) | 31(20.53) |  |
TNM stages (n, %) | Â | Â | 0.182 | Â | Â | 0.613 |
 I stage | 9(13.43) | 43(25.60) |  | 15(17.86) | 37(24.50) |  |
 II stage | 12(17.91) | 25(14.88) |  | 15(17.86) | 22(14.57) |  |
 III stage | 29(43.28) | 70(41.67) |  | 38(45.24) | 61(40.40) |  |
 IV stage | 17(25.37) | 30(17.86) |  | 16(19.05) | 31(20.53) |  |
Chemotherapy/radiotherapy (yes, n, %) | 39(58.21) | 110(65.48) | 0.296 | 51(60.71) | 98(64.90) | 0.523 |
Lymphatic metastasis (yes, n, %) | 48(71.64) | 97(57.74) | 0.048 | 58(69.05) | 87(57.62) | 0.084 |
Distant metastasis (yes, n, %) | 17(25.37) | 30(17.86) | 0.193 | 16(19.05) | 31(20.53) | 0.785 |
Alive (yes, n, %) | 14(20.90) | 42(25.00) | 0.505 | 15(17.86) | 41(27.15) | 0.109 |
Overall survival (years, Mean ± SD) | 2.42 ± 1.64 | 3.00 ± 1.71 | 0.018 | 2.57 ± 1.73 | 2.99 ± 1.69 | 0.066 |